February 6, 2025 – A recent publication in Nature Communications presents compelling preclinical evidence supporting MI-883 as a promising therapeutic agent for hypercholesterolemia. The study, titled “The hypolipidemic effect of MI-883, the combined CAR agonist/PXR antagonist, in diet-induced hypercholesterolemia model,” demonstrates that MI-883, a dual-function compound, effectively lowers plasma cholesterol levels and enhances bile acid excretion. https://doi.org/10.1038/s41467-025-56642-y
By selectively modulating the nuclear receptors CAR and PXR, MI-883 offers a novel approach to managing lipid disorders, potentially addressing the limitations of current therapies.
This research underscores MI-883’s potential to fulfill unmet needs in the treatment of severe and genetic forms of hypercholesterolemia.
